Hemostemix (CVE:HEM) Hits New 12-Month Low – What’s Next?

Hemostemix Inc. (CVE:HEM) hit a new 52-week low on Friday . The company traded as low as C$0.08 and last traded at C$0.08, with a volume of 1024 shares changing hands. The stock had previously closed at C$0.09.

Hemostemix Price Performance

The company has a 50 day moving average of C$0.09 and a 200-day moving average of C$0.09. The stock has a market capitalization of C$15.08 million, a P/E ratio of -2.96 and a beta of 0.25. The company has a quick ratio of 0.48, a current ratio of 1.54 and a debt-to-equity ratio of -99.52.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.